

# A Study of SGT-003 Gene Therapy in Duchenne Muscular Dystrophy (INSPIRE DUCHENNE)

NCT06138639

---

Status	RECRUITING
Phase	Phase 1, Phase 2
Sponsor	Solid Biosciences Inc.
Enrollment	60 participants

## Key Eligibility Criteria

---

### Inclusion (18)

- Cohort 1: 4 to <7 years of age
- Cohort 2: 7 to <12 years of age
- Cohort 3: 0 to < 4 years of age
- Cohort 4: 12 to < 18 years of age
- Cohort 5: 10 to < 18 years of age
- ... and 13 more (see full listing online)

### Exclusion (4)

- Treatment with dystrophin modifying drugs within 3 months prior to screening.
- Current or prior treatment with an approved or investigational gene transfer drug.
- Exposure to certain approved or investigational drugs within 3 months prior to screening or 5 half-lives since last administration, whichever is longer.
- Established clinical diagnosis of DMD that is associated with any deletion mutation invariant or variant predicted to not express exons 1 to 11 or, exons 42 to 45, or exons 57 to 69, inclusive, in the DMD gene as documented by a genetic report and confirmed by Sponsor genetic testing.

## Locations (15 total)

---

Arkansas Children's Hospital, Little Rock, Arkansas, United States  
University of California, Los Angeles Medical Center, Los Angeles, California, United States  
University of California, Davis, Sacramento, California, United States  
... and 12 more locations

---

<https://clinicaltrials.gov/study/NCT06138639>

DISCLAIMER: This document is for informational purposes only and does not constitute medical advice. Always consult your healthcare provider before enrolling in any clinical trial. Information may not be up to date — verify details at [ClinicalTrials.gov](https://clinicaltrials.gov). Generated by [ClinicalTrialsFinder.org](https://clinicaltrialsfinder.org).